Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
clinical trial enrollment times by up to half, highlighting meaningful cost efficiencies across its development pipeline. The company also indicated that its upcoming quarterly results are expected to show an EPS loss of US$0.27 with revenue growing around 41% year over year, underscoring how rapid AI-enabled R&D advances are coinciding with ongoing investment and losses. We'll now examine how Recursion's acceleration in AI-enabled target discovery and faster clinical enrollment may reshape its existing investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recursion Pharmaceuticals Investment Narrative Recap To own Recursion today, you need to believe its AI-first Recursion OS can turn faster, cheaper drug discovery
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6GlobeNewswire
- Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals May Be Losing Ground To Its Peers [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities [Yahoo! Finance]Yahoo! Finance
- A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 4/24/26 - Form 4
- 4/24/26 - Form SCHEDULE
- 4/22/26 - Form 144
- RXRX's page on the SEC website